Neurotransmitters and neuropeptides in depression

Handbook of Clinical Neurology

Volumn 106, Issue , 2012, Pages 107-136

  Bao, A M ^a,b   Ruhe H G ^c   Gao, S F ^a   Swaab, D F ^b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84861177227     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52002-9.00008-5     Document Type: Chapter

References (277)

1. Akil H. Stressed and depressed. Nat Med 2005, 11:116-118.
2. Allen P.P., Cleare A.J., Lee F., et al. Effect of acute tryptophan depletion on pre-frontal engagement. Psychopharmacology (Berl) 2006, 187:486-497.
3. Anguelova M., Benkelfat C., Turecki G. A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter: I. Affective disorders. Mol Psychiatry 2003, 8:574-591.
4. Arranz B., Cowburn R., Eriksson A., et al. Gamma-aminobutyric acid-B (GABAB) binding sites in postmortem suicide brains. Neuropsychobiology 1992, 26:33-36.
5. Auer D.P., Putz B., Kraft E., et al. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 2000, 47:305-313.
6. Bach-Mizrachi H., Underwood M.D., Tin A., et al. Elevated expression of tryptophan hydroxylase-2 mRNA at the neuronal level in the dorsal and median raphe nuclei of depressed suicides. Mol Psychiatry 2008, 13:507-513. 465.
7. Bao A.M., Swaab D.F. Gender difference in age-related number of corticotropin-releasing hormone-expressing neurons in the human hypothalamic paraventricular nucleus and the role of sex hormones. Neuroendocrinology 2007, 85:27-36.
8. Bao A.M., Ji Y.F., Van Someren E.J., et al. Diurnal rhythms of free estradiol and cortisol during the normal menstrual cycle in women with major depression. Horm Behav 2004, 45:93-102.
9. Bao A.M., Hestiantoro A., Van Someren E.J., et al. Colocalization of corticotropin-releasing hormone and oestrogen receptor-alpha in the paraventricular nucleus of the hypothalamus in mood disorders. Brain 2005, 128:1301-1313.
10. Bao A.M., Fischer D.F., Wu Y.H., et al. A direct androgenic involvement in the expression of human corticotropin-releasing hormone. Mol Psychiatry 2006, 11:567-576.
11. Bao A.M., Meynen G., Swaab D.F. The stress system in depression and neurodegeneration: focus on the human hypothalamus. Brain Res Rev 2008, 57:531-553.
12. Barden N. Modulation of glucocorticoid receptor gene expression by antidepressant drugs. Pharmacopsychiatry 1996, 29:12-22.
13. Bartanusz V., Jezova D., Bertini L.T., et al. Stress-induced increase in vasopressin and corticotropin-releasing factor expression in hypophysiotrophic paraventricular neurons. Endocrinology 1993, 132:895-902.
14. Bartanusz V., Muller D., Gaillard R.C., et al. Local gamma-aminobutyric acid and glutamate circuit control of hypophyseotrophic corticotropin-releasing factor neuron activity in the paraventricular nucleus of the hypothalamus. Eur J Neurosci 2004, 19:777-782.
15. Baumann B., Bielau H., Krell D., et al. Circumscribed numerical deficit of dorsal raphe neurons in mood disorders. Psychol Med 2002, 32:93-103.
16. Bell C., Abrams J., Nutt D. Tryptophan depletion and its implications for psychiatry. Br J Psychiatry 2001, 178:399-405.
17. Belmaker R.H. The future of depression psychopharmacology. CNS Spectr 2008, 13:682-687.
18. Belmaker R.H., Agam G. Major depressive disorder. N Engl J Med 2008, 358:55-68.
19. Benes F.M., Todtenkopf M.S., Logiotatos P., et al. Glutamate decarboxylase(65)-immunoreactive terminals in cingulate and prefrontal cortices of schizophrenic and bipolar brain. J Chem Neuroanat 2000, 20:259-269.
20. Benes F.M., Vincent S.L., Todtenkopf M. The density of pyramidal and nonpyramidal neurons in anterior cingulate cortex of schizophrenic and bipolar subjects. Biol Psychiatry 2001, 50:395-406.
21. Beneyto M., Kristiansen L.V., Oni-Orisan A., et al. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 2007, 32:1888-1902.
22. Berman R.M., Cappiello A., Anand A., et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000, 47:351-354.
23. Bhagwagar Z., Wylezinska M., Jezzard P., et al. Reduction in occipital cortex gamma-aminobutyric acid concentrations in medication-free recovered unipolar depressed and bipolar subjects. Biol Psychiatry 2007, 61:806-812.
24. Bhagwagar Z., Wylezinska M., Jezzard P., et al. Low GABA concentrations in occipital cortex and anterior cingulate cortex in medication-free, recovered depressed patients. Int J Neuropsychopharmacol 2008, 11:255-260.
25. Bielau H., Steiner J., Mawrin C., et al. Dysregulation of GABAergic neurotransmission in mood disorders: a postmortem study. Ann N Y Acad Sci 2007, 1096:157-169.
26. Booij L., Van der Does A.J., Riedel W.J. Monoamine depletion in psychiatric and healthy populations: review. Mol Psychiatry 2003, 8:951-973.
27. Boudaba C., Szabo K., Tasker J.G. Physiological mapping of local inhibitory inputs to the hypothalamic paraventricular nucleus. J Neurosci 1996, 16:7151-7160.
28. Boudaba C., Schrader L.A., Tasker J.G. Physiological evidence for local excitatory synaptic circuits in the rat hypothalamus. J Neurophysiol 1997, 77:3396-3400.
29. Bowley M.P., Drevets W.C., Ongur D., et al. Low glial numbers in the amygdala in major depressive disorder. Biol Psychiatry 2002, 52:404-412.
30. Bremner J.D., Innis R.B., Salomon R.M., et al. Positron emission tomography measurement of cerebral metabolic correlates of tryptophan depletion-induced depressive relapse. Arch Gen Psychiatry 1997, 54:364-374.
31. Bremner J.D., Vythilingam M., Ng C.K., et al. Regional brain metabolic correlates of alpha-methylparatyrosine-induced depressive symptoms: implications for the neural circuitry of depression. JAMA 2003, 289:3125-3134.
32. Brundin L., Bjorkqvist M., Petersen A., et al. Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. Eur Neuropsychopharmacol 2007, 17:573-579.
33. Brundin L., Bjorkqvist M., Traskman-Bendz L., et al. Increased orexin levels in the cerebrospinal fluid the first year after a suicide attempt. J Affect Disord 2009, 113:179-182.
34. Carpenter L.L., Schecter J.M., Tyrka A.R., et al. Open-label tiagabine monotherapy for major depressive disorder with anxiety. J Clin Psychiatry 2006, 67:66-71.
35. Castillo M., Kwock L., Courvoisie H., et al. Proton MR spectroscopy in children with bipolar affective disorder: preliminary observations. AJNR Am J Neuroradiol 2000, 21:832-838.
36. Charney D.S. Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry 1998, 59:11-14.
37. Cheetham S.C., Crompton M.R., Katona C.L., et al. Brain GABAA/benzodiazepine binding sites and glutamic acid decarboxylase activity in depressed suicide victims. Brain Res 1988, 460:114-123.
38. Chen C.H., Ridler K., Suckling J., et al. Brain imaging correlates of depressive symptom severity and predictors of symptom improvement after antidepressant treatment. Biol Psychiatry 2007, 62:407-414.
39. Choudary P.V., Molnar M., Evans S.J., et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci U S A 2005, 102:15653-15658.
40. Christiansen L., Tan Q., Iachina M., et al. Candidate gene polymorphisms in the serotonergic pathway: influence on depression symptomatology in an elderly population. Biol Psychiatry 2007, 61:223-230.
41. Clark P.M. Programming of the hypothalamo-pituitary-adrenal axis and the fetal origins of adult disease hypothesis. Eur J Pediatr 1998, 157:S7-S10.
42. Cools R., Calder A.J., Lawrence A.D., et al. Individual differences in threat sensitivity predict serotonergic modulation of amygdala response to fearful faces. Psychopharmacology (Berl) 2005, 180:670-679.
43. Coric V., Milanovic S., Wasylink S., et al. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharmacology (Berl) 2003, 167:219-220.
44. Cowen P.J. Serotonin and depression: pathophysiological mechanism or marketing myth?. Trends Pharmacol Sci 2008, 29:433-436.
45. Cross J.A., Cheetham S.C., Crompton M.R., et al. Brain GABAB binding sites in depressed suicide victims. Psychiatry Res 1988, 26:119-129.
46. Cryan J.F., Kaupmann K. Don't worry 'B' happy!: a role for GABA(B) receptors in anxiety and depression. Trends Pharmacol Sci 2005, 26:36-43.
47. Curtis A.L., Lechner S.M., Pavcovich L.A., et al. Activation of the locus coeruleus noradrenergic system by intracoerulear microinfusion of corticotropin-releasing factor: effects on discharge rate, cortical norepinephrine levels and cortical electroencephalographic activity. J Pharmacol Exp Ther 1997, 281:163-172.
48. Czyrak A., Chocyk A., Mackowiak M., et al. Distribution of dopamine D1 receptors in the nucleus paraventricularis of the hypothalamus in rats: an immunohistochemical study. Brain Res Mol Brain Res 2000, 85:209-217.
49. Damadzic R., Shuangshoti S., Giblen G., et al. Neuritic pathology is lacking in the entorhinal cortex, subiculum and hippocampus in middle-aged adults with schizophrenia, bipolar disorder or unipolar depression. Acta Neuropathol 2002, 103:488-494.
50. Damasio A.R. Descartes' error: emotion, reason, and the human brain 1994, G.P., Putnam, New York.
51. de Goeij D.C., Kvetnansky R., Whitnall M.H., et al. Repeated stress-induced activation of corticotropin-releasing factor neurons enhances vasopressin stores and colocalization with corticotropin-releasing factor in the median eminence of rats. Neuroendocrinology 1991, 53:150-159.
52. Delgado P.L. Monoamine depletion studies: implications for antidepressant discontinuation syndrome. J Clin Psychiatry 2006, 67:22-26.
53. Delgado P.L., Miller H.L., Salomon R.M., et al. Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacol Bull 1993, 29:389-396.
54. Dempster E.L., Burcescu I., Wigg K., et al. Evidence of an association between the vasopressin V1b receptor gene (AVPR1B) and childhood-onset mood disorders. Arch Gen Psychiatry 2007, 64:1189-1195.
55. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
56. de Winter R.F., van Hemert A.M., DeRijk R.H., et al. Anxious-retarded depression: relation with plasma vasopressin and cortisol. Neuropsychopharmacology 2003, 28:140-147.
57. Dinan T.G., Lavelle E., Cooney J., et al. Dexamethasone augmentation in treatment-resistant depression. Acta Psychiatr Scand 1997, 95:58-61.
58. Dinan T.G., O'Brien S., Lavelle E., et al. Further neuroendocrine evidence of enhanced vasopressin V3 receptor responses in melancholic depression. Psychol Med 2004, 34:169-172.
59. Doornbos B., Dijck-Brouwer D.A., Kema I.P., et al. The development of peripartum depressive symptoms is associated with gene polymorphisms of MAOA, 5-HTT and COMT. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:1250-1254.
60. Dowlatshahi D., MacQueen G., Wang J.F., et al. Increased hippocampal supragranular Timm staining in subjects with bipolar disorder. Neuroreport 2000, 11:3775-3778.
61. Drevets W.C., Ongur D., Price J.L. Neuroimaging abnormalities in the subgenual prefrontal cortex: implications for the pathophysiology of familial mood disorders. Mol Psychiatry 1998, 3:220-226. 190-1.
62. Drevets W.C., Price J.L., Furey M.L. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct 2008, 213:93-118.
63. Dunham J.S., Deakin J.F., Miyajima F., et al. Expression of hippocampal brain-derived neurotrophic factor and its receptors in Stanley consortium brains. J Psychiatr Res 2009, 43:1175-1184.
64. Dunn A.J. Stress-related activation of cerebral dopaminergic systems. Ann N Y Acad Sci 1988, 537:188-205.
65. Eastwood S.L., Harrison P.J. Hippocampal synaptic pathology in schizophrenia, bipolar disorder and major depression: a study of complexin mRNAs. Mol Psychiatry 2000, 5:425-432.
66. Eaton M.J., Cheung S., Moore K.E., et al. Dopamine receptor-mediated regulation of corticotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. Brain Res 1996, 738:60-66.
67. Engelmann M., Landgraf R., Wotjak C.T. The hypothalamic-neurohypophysial system regulates the hypothalamic-pituitary-adrenal axis under stress: an old concept revisited. Front Neuroendocrinol 2004, 25:132-149.
68. Erkut Z.A., Pool C., Swaab D.F. Glucocorticoids suppress corticotropin-releasing hormone and vasopressin expression in human hypothalamic neurons. J Clin Endocrinol Metab 1998, 83:2066-2073.
69. Erkut Z.A., Gabreels B.A., Eikelenboom J., et al. Glucocorticoid treatment is associated with decreased expression of processed AVP but not of proAVP, neurophysin or oxytocin in the human hypothalamus: are PC1 and PC2 involved?. Neuro Endocrinol Lett 2002, 23:33-44.
70. Evers E.A., Cools R., Clark L., et al. Serotonergic modulation of prefrontal cortex during negative feedback in probabilistic reversal learning. Neuropsychopharmacology 2005, 30:1138-1147.
71. Evers E.A., van der Veen F.M., Jolles J., et al. Acute tryptophan depletion improves performance and modulates the BOLD response during a Stroop task in healthy females. Neuroimage 2006, 32:248-255.
72. Evers E.A., van der Veen F.M., van Deursen J.A., et al. The effect of acute tryptophan depletion on the BOLD response during performance monitoring and response inhibition in healthy male volunteers. Psychopharmacology (Berl) 2006, 187:200-208.
73. Fatemi S.H., Stary J.M., Earle J.A., et al. GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 kDa and Reelin proteins in cerebellum. Schizophr Res 2005, 72:109-122.
74. Feldman S., Weidenfeld J. Hypothalamic mechanisms mediating glutamate effects on the hypothalamo-pituitary-adrenocortical axis. J Neural Transm 1997, 104:633-642.
75. Fornito A., Yucel M., Wood S.J., et al. Anterior cingulate cortex abnormalities associated with a first psychotic episode in bipolar disorder. Br J Psychiatry 2009, 194:426-433.
76. Fountoulakis K.N., Giannakopoulos P., Kovari E., et al. Assessing the role of cingulate cortex in bipolar disorder: neuropathological, structural and functional imaging data. Brain Res Rev 2008, 59:9-21.
77. Frank E., Landgraf R. The vasopressin system - from antidiuresis to psychopathology. Eur J Pharmacol 2008, 583:226-242.
78. Fremeau R.T., Duncan G.E., Fornaretto M.G., et al. Localization of D1 dopamine receptor mRNA in brain supports a role in cognitive, affective, and neuroendocrine aspects of dopaminergic neurotransmission. Proc Natl Acad Sci U S A 1991, 88:3772-3776.
79. Frye M.A., Watzl J., Banakar S., et al. Increased anterior cingulate/medial prefrontal cortical glutamate and creatine in bipolar depression. Neuropsychopharmacology 2007, 32:2490-2499.
80. Fusar-Poli P., Allen P., McGuire P., et al. Neuroimaging and electrophysiological studies of the effects of acute tryptophan depletion: a systematic review of the literature. Psychopharmacology (Berl) 2006, 188:131-143.
81. Gillies G.E., Linton E.A., Lowry P.J. Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin. Nature 1982, 299:355-357.
82. Gimpl G., Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev 2001, 81:629-683.
83. Gispen-de Wied C.C., Westenberg H.G., Koppeschaar H.P., et al. Stimulation of the pituitary-adrenal axis with a low dose [Arg8]-vasopressin in depressed patients and healthy subjects. Eur Neuropsychopharmacol 1992, 2:411-419.
84. Goekoop J.G., de Winter R.P., de Rijk R., et al. Depression with above-normal plasma vasopressin: validation by relations with family history of depression and mixed anxiety and retardation. Psychiatry Res 2006, 141:201-211.
85. Gorman J.M. New molecular targets for antianxiety interventions. J Clin Psychiatry 2003, 64:28-35.
86. Gos T., Gunther K., Bielau H., et al. Suicide and depression in the quantitative analysis of glutamic acid decarboxylase-immunoreactive neuropil. J Affect Disord 2009, 113:45-55.
87. Grahn R.E., Will M.J., Hammack S.E., et al. Activation of serotonin-immunoreactive cells in the dorsal raphe nucleus in rats exposed to an uncontrollable stressor. Brain Res 1999, 826:35-43.
88. Gratton A. Time course analysis of para-chlorophenylalanine induced suppression of self-stimulation behavior. Pharmacol Biochem Behav 1982, 17:597-602.
89. Greenwood B.N., Foley T.E., Day H.E., et al. Freewheel running prevents learned helplessness/behavioral depression: role of dorsal raphe serotonergic neurons. J Neurosci 2003, 23:2889-2898.
90. Griffiths J., Ravindran A.V., Merali Z., et al. Dysthymia: a review of pharmacological and behavioral factors. Mol Psychiatry 2000, 5:242-261.
91. Guidotti A., Auta J., Davis J.M., et al. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry 2000, 57:1061-1069.
92. Hamidi M., Drevets W.C., Price J.L. Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes. Biol Psychiatry 2004, 55:563-569.
93. Harrison P.J. The neuropathology of primary mood disorder. Brain 2002, 125:1428-1449.
94. Hasler G., van der Veen J.W., Tumonis T., et al. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry 2007, 64:193-200.
95. Heckers S., Stone D., Walsh J., et al. Differential hippocampal expression of glutamic acid decarboxylase 65 and 67 messenger RNA in bipolar disorder and schizophrenia. Arch Gen Psychiatry 2002, 59:521-529.
96. Hendricksen M., Thomas A.J., Ferrier I.N., et al. Neuropathological study of the dorsal raphe nuclei in late-life depression and Alzheimer's disease with and without depression. Am J Psychiatry 2004, 161:1096-1102.
97. Herman J.P., Mueller N.K., Figueiredo H. Role of GABA and glutamate circuitry in hypothalamo-pituitary-adrenocortical stress integration. Ann N Y Acad Sci 2004, 1018:35-45.
98. Heuser I., Bissette G., Dettling M., et al. Cerebrospinal fluid concentrations of corticotropin-releasing hormone, vasopressin, and somatostatin in depressed patients and healthy controls: response to amitriptyline treatment. Depress Anxiety 1998, 8:71-79.
99. Hirschfeld R.M. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry 2000, 61:4-6.
100. Hofman M.A., Swaab D.F. Seasonal changes in the suprachiasmatic nucleus of man. Neurosci Lett 1992, 139:257-260.
101. Hofman M.A., Swaab D.F. Diurnal and seasonal rhythms of neuronal activity in the suprachiasmatic nucleus of humans. J Biol Rhythms 1993, 8:283-295.
102. Holemans S., De Paermentier F., Horton R.W., et al. NMDA glutamatergic receptors, labelled with [3H]MK-801, in brain samples from drug-free depressed suicides. Brain Res 1993, 616:138-143.
103. Holsboer F. Stress, hypercortisolism and corticosteroid receptors in depression: implications for therapy. J Affect Disord 2001, 62:77-91.
104. Hood S.D., Bell C.J., Nutt D.J. Acute tryptophan depletion. Part I: rationale and methodology. Aust N Z J Psychiatry 2005, 39:558-564.
105. Hoogendijk W.J., Meynen G., Endert E., et al. Increased cerebrospinal fluid cortisol level in Alzheimer's disease is not related to depression. Neurobiol Aging 2006, 27:780. e1-780.e2.
106. Hsu D.T., Lombardo K.A., Herringa R.J., et al. Corticotropin-releasing hormone messenger RNA distribution and stress-induced activation in the thalamus. Neuroscience 2001, 105:911-921.
107. Inder W.J., Donald R.A., Prickett T.C., et al. Arginine vasopressin is associated with hypercortisolemia and suicide attempts in depression. Biol Psychiatry 1997, 42:744-747.
108. Ishunina T.A., Salehi A., Hofman M.A., et al. Activity of vasopressinergic neurones of the human supraoptic nucleus is age- and sex-dependent. J Neuroendocrinol 1999, 11:251-258.
109. Itoi K., Helmreich D.L., Lopez-Figueroa M.O., et al. Differential regulation of corticotropin-releasing hormone and vasopressin gene transcription in the hypothalamus by norepinephrine. J Neurosci 1999, 19:5464-5472.
110. Janssen J., Hulshoff Pol H.E., Lampe I.K., et al. Hippocampal changes and white matter lesions in early-onset depression. Biol Psychiatry 2004, 56:825-831.
111. Johansson C., Willeit M., Smedh C., et al. Circadian clock-related polymorphisms in seasonal affective disorder and their relevance to diurnal preference. Neuropsychopharmacology 2003, 28:734-739.
112. Kalsbeek A., Buijs R.M., van Heerikhuize J.J., et al. Vasopressin-containing neurons of the suprachiasmatic nuclei inhibit corticosterone release. Brain Res 1992, 580:62-67.
113. Kalsbeek A., Verhagen L.A., Schalij I., et al. Opposite actions of hypothalamic vasopressin on circadian corticosterone rhythm in nocturnal versus diurnal species. Eur J Neurosci 2008, 27:818-827.
114. Karolewicz B., Stockmeier C.A., Ordway G.A. Elevated levels of the NR2C subunit of the NMDA receptor in the locus coeruleus in depression. Neuropsychopharmacology 2005, 30:1557-1567.
115. Keeney A., Jessop D.S., Harbuz M.S., et al. Differential effects of acute and chronic social defeat stress on hypothalamic-pituitary-adrenal axis function and hippocampal serotonin release in mice. J Neuroendocrinol 2006, 18:330-338.
116. Kempton M.J., Geddes J.R., Ettinger U., et al. Meta-analysis, database, and meta-regression of 98 structural imaging studies in bipolar disorder. Arch Gen Psychiatry 2008, 65:1017-1032.
117. Kishi T., Kitajima T., Ikeda M., et al. Association study of clock gene (CLOCK) and schizophrenia and mood disorders in the Japanese population. Eur Arch Psychiatry Clin Neurosci 2009, 259:293-297.
118. Klaassen T., Riedel W.J., van Praag H.M., et al. Neuroendocrine response to meta-chlorophenylpiperazine and ipsapirone in relation to anxiety and aggression. Psychiatry Res 2002, 113:29-40.
119. Knable M.B., Barci B.M., Webster M.J., et al. Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the Stanley Neuropathology Consortium. Mol Psychiatry 2004, 9(609-620):544.
120. Kovacs K.J., Miklos I.H., Bali B. GABAergic mechanisms constraining the activity of the hypothalamo-pituitary-adrenocortical axis. Ann N Y Acad Sci 2004, 1018:466-476.
121. Kudoh A., Takahira Y., Katagai H., et al. Small-dose ketamine improves the postoperative state of depressed patients. Anesth Analg 2002, 95:114-118.
122. Landfield P.W., Baskin R.K., Pitler T.A. Brain aging correlates: retardation by hormonal-pharmacological treatments. Science 1981, 214:581-584.
123. Landgraf R., Kessler M.S., Bunck M., et al. Candidate genes of anxiety-related behavior in HAB/LAB rats and mice: focus on vasopressin and glyoxalase-I. Neurosci Biobehav Rev 2007, 31:89-102.
124. Law A.J., Deakin J.F. Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. Neuroreport 2001, 12:2971-2974.
125. Legros J.J. Inhibitory effect of oxytocin on corticotrope function in humans: are vasopressin and oxytocin ying-yang neurohormones?. Psychoneuroendocrinology 2001, 26:649-655.
126. Leonard B.E. Psychopathology of depression. Drugs Today (Barc) 2007, 43:705-716.
127. Liposits Z., Phelix C., Paull W.K. Synaptic interaction of serotonergic axons and corticotropin releasing factor (CRF) synthesizing neurons in the hypothalamic paraventricular nucleus of the rat. A light and electron microscopic immunocytochemical study. Histochemistry 1987, 86:541-549.
128. Liu R.Y., Zhou J.N., Hoogendijk W.J., et al. Decreased vasopressin gene expression in the biological clock of Alzheimer disease patients with and without depression. J Neuropathol Exp Neurol 2000, 59:314-322.
129. Liu R.Y., Unmehopa U.A., Zhou J.N., et al. Glucocorticoids suppress vasopressin gene expression in human suprachiasmatic nucleus. J Steroid Biochem Mol Biol 2006, 98:248-253.
130. Liu Z., Zhu F., Wang G., et al. Association of corticotropin-releasing hormone receptor1 gene SNP and haplotype with major depression. Neurosci Lett 2006, 404:358-362.
131. Liu G.X., Cai G.Q., Cai Y.Q., et al. Reduced anxiety and depression-like behaviors in mice lacking GABA transporter subtype 1. Neuropsychopharmacology 2007, 32:1531-1539.
132. Lolait S.J., Stewart L.Q., Jessop D.S., et al. The hypothalamic-pituitary-adrenal axis response to stress in mice lacking functional vasopressin V1b receptors. Endocrinology 2007, 148:849-856.
133. Lotrich F.E., Pollock B.G. Meta-analysis of serotonin transporter polymorphisms and affective disorders. Psychiatr Genet 2004, 14:121-129.
134. Lu A., Steiner M.A., Whittle N., et al. Conditional mouse mutants highlight mechanisms of corticotropin-releasing hormone effects on stress-coping behavior. Mol Psychiatry 2008, 13:1028-1042.
135. Lu A., Steiner M.A., Whittle N., et al. Conditional CRH overexpressing mice: an animal model for stress-elicited pathologies and treatments that target the central CRH system. Mol Psychiatry 2008, 13:989.
136. Lucassen P.J., Muller M.B., Holsboer F., et al. Hippocampal apoptosis in major depression is a minor event and absent from subareas at risk for glucocorticoid overexposure. Am J Pathol 2001, 158:453-468.
137. Ludwig M., Bull P.M., Tobin V.A., et al. Regulation of activity-dependent dendritic vasopressin release from rat supraoptic neurones. J Physiol 2005, 564:515-522.
138. Lund T.D., Munson D.J., Haldy M.E., et al. Androgen inhibits, while oestrogen enhances, restraint-induced activation of neuropeptide neurones in the paraventricular nucleus of the hypothalamus. J Neuroendocrinol 2004, 16:272-278.
139. Maswood S., Barter J.E., Watkins L.R., et al. Exposure to inescapable but not escapable shock increases extracellular levels of 5-HT in the dorsal raphe nucleus of the rat. Brain Res 1998, 783:115-120.
140. McCullumsmith R.E., Meador-Woodruff J.H. Striatal excitatory amino acid transporter transcript expression in schizophrenia, bipolar disorder, and major depressive disorder. Neuropsychopharmacology 2002, 26:368-375.
141. McCullumsmith R.E., Kristiansen L.V., Beneyto M., et al. Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder. Brain Res 2007, 1127:108-118.
142. McEwen B.S. Glucocorticoids, depression, and mood disorders: structural remodeling in the brain. Metabolism 2005, 54:20-23.
143. McIntosh A.M., Moorhead T.W., McKirdy J., et al. Prefrontal gyral folding and its cognitive correlates in bipolar disorder and schizophrenia. Acta Psychiatr Scand 2009, 119:192-198.
144. Merali Z., Du L., Hrdina P., et al. Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region. J Neurosci 2004, 24:1478-1485.
145. Merali Z., Kent P., Du L., et al. Corticotropin-releasing hormone, arginine vasopressin, gastrin-releasing peptide, and neuromedin B alterations in stress-relevant brain regions of suicides and control subjects. Biol Psychiatry 2006, 59:594-602.
146. Meyer-Bahlburg H.F.L., Ehrhardt A.A. A prenatal-hormone hypothesis for depression in adults with a history of fetal DES exposure. Hormones and Depression 2003, 325-338. Raven Press, New York.
147. Meynen G., Unmehopa U.A., van Heerikhuize J.J., et al. Increased arginine vasopressin mRNA expression in the human hypothalamus in depression: a preliminary report. Biol Psychiatry 2006, 60:892-895.
148. Meynen G., Unmehopa U.A., Hofman M.A., et al. Hypothalamic oxytocin mRNA expression and melancholic depression. Mol Psychiatry 2007, 12:118-119.
149. Meynen G., Unmehopa U.A., Hofman M.A., et al. Relation between corticotropin-releasing hormone neuron number in the hypothalamic paraventricular nucleus and depressive state in Alzheimer's disease. Neuroendocrinology 2007, 85:37-44.
150. Meynen G., Unmehopa U.A., Hofman M.A., et al. Hypothalamic vasopressin and oxytocin mRNA expression in relation to depressive state in Alzheimer's disease: a difference with major depressive disorder. J Neuroendocrinol 2009, 21:722-729.
151. Michael N., Erfurth A., Ohrmann P., et al. Neurotrophic effects of electroconvulsive therapy: a proton magnetic resonance study of the left amygdalar region in patients with treatment-resistant depression. Neuropsychopharmacology 2003, 28:720-725.
152. Michael N., Gosling M., Reutemann M., et al. Metabolic changes after repetitive transcranial magnetic stimulation (rTMS) of the left prefrontal cortex: a sham-controlled proton magnetic resonance spectroscopy (1H MRS) study of healthy brain. Eur J Neurosci 2003, 17:2462-2468.
153. Miller A.L. Epidemiology, etiology, and natural treatment of seasonal affective disorder. Altern Med Rev 2005, 10:5-13.
154. Miller G. Neuroscience. The dark side of glia. Science 2005, 308:778-781.
155. Mirza Y., Tang J., Russell A., et al. Reduced anterior cingulate cortex glutamatergic concentrations in childhood major depression. J Am Acad Child Adolesc Psychiatry 2004, 43:341-348.
156. Mlynarik M., Zelena D., Bagdy G., et al. Signs of attenuated depression-like behavior in vasopressin deficient Brattleboro rats. Horm Behav 2007, 51:395-405.
157. Moja E.A., Lucini V., Benedetti F., et al. Decrease in plasma phenylalanine and tyrosine after phenylalanine-tyrosine free amino acid solutions in man. Life Sci 1996, 58:2389-2395.
158. Moore P., Landolt H.P., Seifritz E., et al. Clinical and physiological consequences of rapid tryptophan depletion. Neuropsychopharmacology 2000, 23:601-622.
159. Muller M.B., Landgraf R., Keck M.E. Vasopressin, major depression, and hypothalamic-pituitary-adrenocortical desensitization. Biol Psychiatry 2000, 48:330-333.
160. Muller M.B., Lucassen P.J., Yassouridis A., et al. Neither major depression nor glucocorticoid treatment affects the cellular integrity of the human hippocampus. Eur J Neurosci 2001, 14:1603-1612.
161. Neumeister A., Konstantinidis A., Stastny J., et al. Association between serotonin transporter gene promoter polymorphism (5HTTLPR) and behavioral responses to tryptophan depletion in healthy women with and without family history of depression. Arch Gen Psychiatry 2002, 59:613-620.
162. Neumeister A., Nugent A.C., Waldeck T., et al. Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls. Arch Gen Psychiatry 2004, 61:765-773.
163. Neumeister A., Hu X.Z., Luckenbaugh D.A., et al. Differential effects of 5-HTTLPR genotypes on the behavioral and neural responses to tryptophan depletion in patients with major depression and controls. Arch Gen Psychiatry 2006, 63:978-986.
164. Nowak G., Ordway G.A., Paul I.A. Alterations in the N-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res 1995, 675:157-164.
165. Nowak G., Szewczyk B., Sadlik K., et al. Reduced potency of zinc to interact with NMDA receptors in hippocampal tissue of suicide victims. Pol J Pharmacol 2003, 55:455-459.
166. O'Brien J., Thomas A., Ballard C., et al. Cognitive impairment in depression is not associated with neuropathologic evidence of increased vascular or Alzheimer-type pathology. Biol Psychiatry 2001, 49:130-136.
167. Ongur D., Drevets W.C., Price J.L. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci U S A 1998, 95:13290-13295.
168. Osei-Owusu P., James A., Crane J., et al. 5-Hydroxytryptamine 1A receptors in the paraventricular nucleus of the hypothalamus mediate oxytocin and adrenocorticotropin hormone release and some behavioral components of the serotonin syndrome. J Pharmacol Exp Ther 2005, 313:1324-1330.
169. Oswald L.M., Wong D.F., McCaul M., et al. Relationships among ventral striatal dopamine release, cortisol secretion, and subjective responses to amphetamine. Neuropsychopharmacology 2005, 30:821-832.
170. Ozsoy S., Esel E., Kula M. Serum oxytocin levels in patients with depression and the effects of gender and antidepressant treatment. Psychiatry Res 2009, 169:249-252.
171. Pacak K., Armando I., Fukuhara K., et al. Noradrenergic activation in the paraventricular nucleus during acute and chronic immobilization stress in rats: an in vivo microdialysis study. Brain Res 1992, 589:91-96.
172. Pandey G.N., Conley R.R., Pandey S.C., et al. Benzodiazepine receptors in the post-mortem brain of suicide victims and schizophrenic subjects. Psychiatry Res 1997, 71:137-149.
173. Pereira-Lima J.F., Marroni C.P., Pizarro C.B., et al. Immunohistochemical detection of estrogen receptor alpha in pituitary adenomas and its correlation with cellular replication. Neuroendocrinology 2004, 79:119-124.
174. Perry E.K., Gibson P.H., Blessed G., et al. Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J Neurol Sci 1977, 34:247-265.
175. Peterson B.S., Warner V., Bansal R., et al. Cortical thinning in persons at increased familial risk for major depression. Proc Natl Acad Sci U S A 2009, 106:6273-6278.
176. Petroff O.A. GABA and glutamate in the human brain. Neuroscientist 2002, 8:562-573.
177. Pfleiderer B., Michael N., Erfurth A., et al. Effective electroconvulsive therapy reverses glutamate/glutamine deficit in the left anterior cingulum of unipolar depressed patients. Psychiatry Res 2003, 122:185-192.
178. Piazza P.V., Le Moal M.L. Pathophysiological basis of vulnerability to drug abuse: role of an interaction between stress, glucocorticoids, and dopaminergic neurons. Annu Rev Pharmacol Toxicol 1996, 36:359-378.
179. Plotsky P.M. Facilitation of immunoreactive corticotropin-releasing factor secretion into the hypophysial-portal circulation after activation of catecholaminergic pathways or central norepinephrine injection. Endocrinology 1987, 121:924-930.
180. Post R.M. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 1992, 149:999-1010.
181. Praschak-Rieder N., Hussey D., Wilson A.A., et al. Tryptophan depletion and serotonin loss in selective serotonin reuptake inhibitor-treated depression: an [(18)F] MPPF positron emission tomography study. Biol Psychiatry 2004, 56:587-591.
182. Praschak-Rieder N., Wilson A.A., Hussey D., et al. Effects of tryptophan depletion on the serotonin transporter in healthy humans. Biol Psychiatry 2005, 58:825-830.
183. Price J.L., Drevets W.C. Neurocircuitry of mood disorders. Neuropsychopharmacology 2010, 35:192-216.
184. Price R.B., Shungu D.C., Mao X., et al. Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder. Biol Psychiatry 2009, 65:792-800.
185. Pruessner J.C., Champagne F., Meaney M.J., et al. Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care: a positron emission tomography study using [11C]raclopride. J Neurosci 2004, 24:2825-2831.
186. Purba J.S., Hoogendijk W.J., Hofman M.A., et al. Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch Gen Psychiatry 1996, 53:137-143.
187. Raadsheer F.C., Sluiter A.A., Ravid R., et al. Localization of corticotropin-releasing hormone (CRH) neurons in the paraventricular nucleus of the human hypothalamus; age-dependent colocalization with vasopressin. Brain Res 1993, 615:50-62.
188. Raadsheer F.C., Hoogendijk W.J., Stam F.C., et al. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 1994, 60:436-444.
189. Raadsheer F.C., Tilders F.J., Swaab D.F. Similar age related increase of vasopressin colocalization in paraventricular corticotropin-releasing hormone neurons in controls and Alzheimer patients. J Neuroendocrinol 1994, 6:131-133.
190. Raadsheer F.C., van Heerikhuize J.J., Lucassen P.J., et al. Corticotropin-releasing hormone mRNA levels in the paraventricular nucleus of patients with Alzheimer's disease and depression. Am J Psychiatry 1995, 152:1372-1376.
191. Rabadan-Diehl C., Aguilera G. Glucocorticoids increase vasopressin V1b receptor coupling to phospholipase C. Endocrinology 1998, 139:3220-3226.
192. Rajkowska G., Miguel-Hidalgo J.J., Wei J., et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 1999, 45:1085-1098.
193. Rajkowska G., Halaris A., Selemon L.D. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol Psychiatry 2001, 49:741-752.
194. Ranft K., Dobrowolny H., Krell D., et al. Evidence for structural abnormalities of the human habenular complex in affective disorders but not in schizophrenia. Psychol Med 2009, 1-11.
195. Rapp M.A., Schnaider-Beeri M., Grossman H.T., et al. Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry 2006, 63:161-167.
196. Rastogi R.B., Singhal R.L. Evidence for the role of adrenocortical hormones in the regulation of noradrenaline and dopamine metabolism in certain brain areas. Br J Pharmacol 1978, 62:131-136.
197. Reilly J.G., McTavish S.F., Young A.H. Rapid depletion of plasma tryptophan: a review of studies and experimental methodology. J Psychopharmacol 1997, 11:381-392.
198. Riemersma-van der Lek R.F., Swaab D.F., Twisk J., et al. Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial. JAMA 2008, 299:2642-2655.
199. Rivier C., Vale W. Interaction of corticotropin-releasing factor and arginine vasopressin on adrenocorticotropin secretion in vivo. Endocrinology 1983, 113:939-942.
200. Rosenbaum J.F., Fava M., Hoog S.L., et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998, 44:77-87.
201. Rosenberg D.R., Macmaster F.P., Mirza Y., et al. Reduced anterior cingulate glutamate in pediatric major depression: a magnetic resonance spectroscopy study. Biol Psychiatry 2005, 58:700-704.
202. Rouge-Pont F., Deroche V., Le Moal M., et al. Individual differences in stress-induced dopamine release in the nucleus accumbens are influenced by corticosterone. Eur J Neurosci 1998, 10:3903-3907.
203. Roy A., Dejong J., Ferraro T. CSF GABA in depressed patients and normal controls. Psychol Med 1991, 21:613-618.
204. Rubia K., Lee F., Cleare A.J., et al. Tryptophan depletion reduces right inferior prefrontal activation during response inhibition in fast, event-related fMRI. Psychopharmacology (Berl) 2005, 179:791-803.
205. Ruhe H.G., Mason N.S., Schene A.H. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry 2007, 12:331-359.
206. Salomon R.M., Ripley B., Kennedy J.S., et al. Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects. Biol Psychiatry 2003, 54:96-104.
207. Sanacora G., Saricicek A. GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action. CNS Neurol Disord Drug Targets 2007, 6:127-140.
208. Sanacora G., Mason G.F., Rothman D.L., et al. Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 1999, 56:1043-1047.
209. Sanacora G., Gueorguieva R., Epperson C.N., et al. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 2004, 61:705-713.
210. Sapolsky R.M., McEwen B.S. Stress, glucocorticoids, and their role in degenerative changes in the aging hippocampus. Treatment Development Strategies for Alzheimer's Disease 1986, 151-171. Mark Powley, Madison, CT. T. Crook, R.T. Bartens, S. Ferris (Eds.).
211. Scarr E., Pavey G., Sundram S., et al. Decreased hippocampal NMDA, but not kainate or AMPA receptors in bipolar disorder. Bipolar Disord 2003, 5:257-264.
212. Scheithauer B.W., Kovacs K., Zorludemir S., et al. Immunoexpression of androgen receptor in the nontumorous pituitary and in adenomas. Endocr Pathol 2008, 19:27-33.
213. Schmidt E.D., Janszen A.W., Wouterlood F.G., et al. Interleukin-1-induced long-lasting changes in hypothalamic corticotropin-releasing hormone (CRH) - neurons and hyperresponsiveness of the hypothalamus-pituitary-adrenal axis. J Neurosci 1995, 15:7417-7426.
214. Schmidt E.D., Binnekade R., Janszen A.W., et al. Short stressor induced long-lasting increases of vasopressin stores in hypothalamic corticotropin-releasing hormone (CRH) neurons in adult rats. J Neuroendocrinol 1996, 8:703-712.
215. Schmidt M.V., Deussing J.M., Oitzl M.S., et al. Differential disinhibition of the neonatal hypothalamic- pituitary-adrenal axis in brain-specific CRH receptor 1-knockout mice. Eur J Neurosci 2006, 24:2291-2298.
216. Scott L.V., Dinan T.G. Vasopressin and the regulation of hypothalamic-pituitary-adrenal axis function: implications for the pathophysiology of depression. Life Sci 1998, 62:1985-1998.
217. Selye H. A syndrome produced by diverse nocuous agents. 1936. J Neuropsychiatry Clin Neurosci 1998, 10:230-231.
218. Serova L.I., Nankova B.B., Feng Z., et al. Heightened transcription for enzymes involved in norepinephrine biosynthesis in the rat locus coeruleus by immobilization stress. Biol Psychiatry 1999, 45:853-862.
219. Shi J., Wittke-Thompson J.K., Badner J.A., et al. Clock genes may influence bipolar disorder susceptibility and dysfunctional circadian rhythm. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:1047-1055.
220. Shimizu N., Nakane H., Hori T., et al. CRF receptor antagonist attenuates stress-induced noradrenaline release in the medial prefrontal cortex of rats. Brain Res 1994, 654:145-148.
221. Shopsin B., Gershon S., Goldstein M., et al. Use of synthesis inhibitors in defining a role for biogenic amines during imipramine treatment in depressed patients. Psychopharmacol Commun 1975, 1:239-249.
222. Singh V.B., Corley K.C., Phan T.H., et al. Increases in the activity of tryptophan hydroxylase from rat cortex and midbrain in response to acute or repeated sound stress are blocked by adrenalectomy and restored by dexamethasone treatment. Brain Res 1990, 516:66-76.
223. Smagin G.N., Swiergiel A.H., Dunn A.J. Corticotropin-releasing factor administered into the locus coeruleus, but not the parabrachial nucleus, stimulates norepinephrine release in the prefrontal cortex. Brain Res Bull 1995, 36:71-76.
224. Smith K.A., Morris J.S., Friston K.J., et al. Brain mechanisms associated with depressive relapse and associated cognitive impairment following acute tryptophan depletion. Br J Psychiatry 1999, 174:525-529.
225. Stefaneanu L., Kovacs K., Horvath E., et al. In situ hybridization study of estrogen receptor messenger ribonucleic acid in human adenohypophysial cells and pituitary adenomas. J Clin Endocrinol Metab 1994, 78:83-88.
226. Stocks G.M., Cheetham S.C., Crompton M.R., et al. Benzodiazepine binding sites in amygdala and hippocampus of depressed suicide victims. J Affect Disord 1990, 18:11-15.
227. Stryjer R., Strous R.D., Shaked G., et al. Amantadine as augmentation therapy in the management of treatment-resistant depression. Int Clin Psychopharmacol 2003, 18:93-96.
228. Sundman-Eriksson I., Allard P. [(3)H]Tiagabine binding to GABA transporter-1 (GAT-1) in suicidal depression. J Affect Disord 2002, 71:29-33.
229. Sundman I., Allard P., Eriksson A., et al. GABA uptake sites in frontal cortex from suicide victims and in aging. Neuropsychobiology 1997, 35:11-15.
230. Surget A., Belzung C. Involvement of vasopressin in affective disorders. Eur J Pharmacol 2008, 583:340-349.
231. Swaab D.F. The Human Hypothalamus. Basic and Clinical Aspects. Part I: Nuclei of the Hypothalamus. Handbook of Clinical Neurology 2003, Vol. 79. Elsevier, Amsterdam.
232. Swaab D.F. The Human Hypothalamus. Basic and Clinical Aspects. Part II: Neuropathology of the Hypothalamus and Adjacent Brain Structures. Handbook of Clinical Neurology 2004, Vol. 80. Elsevier, Amsterdam.
233. Swaab D.F., Fliers E., Partiman T.S. The suprachiasmatic nucleus of the human brain in relation to sex, age and senile dementia. Brain Res 1985, 342:37-44.
234. Swaab D.F., Raadsheer F.C., Endert E., et al. Increased cortisol levels in aging and Alzheimer's disease in postmortem cerebrospinal fluid. J Neuroendocrinol 1994, 6:681-687.
235. Swaab D.F., Fliers E., Hoogendijk W.J., et al. Interaction of prefrontal cortical and hypothalamic systems in the pathogenesis of depression. Prog Brain Res 2000, 126:369-396.
236. Swaab D.F., Bao A.M., Lucassen P.J. The stress system in the human brain in depression and neurodegeneration. Ageing Res Rev 2005, 4:141-194.
237. Takahashi T., Yucel M., Lorenzetti V., et al. Midline brain structures in patients with current and remitted major depression. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:1058-1063.
238. Takahashi T., Yucel M., Lorenzetti V., et al. Volumetric MRI study of the insular cortex in individuals with current and past major depression. J Affect Disord 2009, 121:231-238.
239. Talbot P.S., Cooper S.J. Anterior cingulate and subgenual prefrontal blood flow changes following tryptophan depletion in healthy males. Neuropsychopharmacology 2006, 31:1757-1767.
240. Taylor M., Murphy S.E., Selvaraj S., et al. Differential effects of citalopram and reboxetine on cortical Glx measured with proton MR spectroscopy. J Psychopharmacol 2008, 22:473-476.
241. Ter Horst G.J., Wichmann R., Gerrits M., et al. Sex differences in stress responses: focus on ovarian hormones. Physiol Behav 2009, 97:239-249.
242. Thierry A.M., Tassin J.P., Blanc G., et al. Selective activation of mesocortical DA system by stress. Nature 1976, 263:242-244.
243. Thompson R.R., George K., Walton J.C., et al. Sex-specific influences of vasopressin on human social communication. Proc Natl Acad Sci U S A 2006, 103:7889-7894.
244. Toro C., Deakin J.F. NMDA receptor subunit NRI and postsynaptic protein PSD-95 in hippocampus and orbitofrontal cortex in schizophrenia and mood disorder. Schizophr Res 2005, 80:323-330.
245. Toro C.T., Hallak J.E., Dunham J.S., et al. Glial fibrillary acidic protein and glutamine synthetase in subregions of prefrontal cortex in schizophrenia and mood disorder. Neurosci Lett 2006, 404:276-281.
246. Trembleau A., Bloom F.E. Subcellular localization of tyrosine hydroxylase (TH) gene transcripts: new insights into the pattern of TH gene expression in the locus coeruleus under pharmacological stimulation. Biol Cell 1998, 90:39-51.
247. Underwood M.D., Khaibulina A.A., Ellis S.P., et al. Morphometry of the dorsal raphe nucleus serotonergic neurons in suicide victims. Biol Psychiatry 1999, 46:473-483.
248. Vamvakopoulos N.C., Chrousos G.P. Evidence of direct estrogenic regulation of human corticotropin-releasing hormone gene expression. Potential implications for the sexual dimorphism of the stress response and immune/inflammatory reaction. J Clin Invest 1993, 92:1896-1902.
249. Van der Does A.J. The effects of tryptophan depletion on mood and psychiatric symptoms. J Affect Disord 2001, 64:107-119.
250. van der Veen F.M., Evers E.A., Deutz N.E., et al. Effects of acute tryptophan depletion on mood and facial emotion perception related brain activation and performance in healthy women with and without a family history of depression. Neuropsychopharmacology 2007, 32:216-224.
251. van Londen L., Goekoop J.G., van Kempen G.M., et al. Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacology 1997, 17:284-292.
252. van Londen L., Goekoop J.G., Zwinderman A.H., et al. Neuropsychological performance and plasma cortisol, arginine vasopressin and oxytocin in patients with major depression. Psychol Med 1998, 28:275-284.
253. van Londen L., Kerkhof G.A., van den Berg F., et al. Plasma arginine vasopressin and motor activity in major depression. Biol Psychiatry 1998, 43:196-204.
254. van Londen L., Goekoop J.G., Kerkhof G.A., et al. Weak 24-h periodicity of body temperature and increased plasma vasopressin in melancholic depression. Eur Neuropsychopharmacol 2001, 11:7-14.
255. van West D., Del-Favero J., Aulchenko Y., et al. A major SNP haplotype of the arginine vasopressin 1B receptor protects against recurrent major depression. Mol Psychiatry 2004, 9:287-292.
256. Vawter M.P., Freed W.J., Kleinman J.E. Neuropathology of bipolar disorder. Biol Psychiatry 2000, 48:486-504.
257. Verkuyl J.M., Hemby S.E., Joels M. Chronic stress attenuates GABAergic inhibition and alters gene expression of parvocellular neurons in rat hypothalamus. Eur J Neurosci 2004, 20:1665-1673.
258. Walter M., Henning A., Grimm S., et al. The relationship between aberrant neuronal activation in the pregenual anterior cingulate, altered glutamatergic metabolism, and anhedonia in major depression. Arch Gen Psychiatry 2009, 66:478-486.
259. Walum H., Westberg L., Henningsson S., et al. Genetic variation in the vasopressin receptor 1a gene (AVPR1A) associates with pair-bonding behavior in humans. Proc Natl Acad Sci U S A 2008, 105:14153-14156.
260. Wang S.S., Kamphuis W., Huitinga I., et al. Gene expression analysis in the human hypothalamus in depression by laser microdissection and real-time PCR: the presence of multiple receptor imbalances. Mol Psychiatry 2008, 13(786-799):741.
261. Weninger S.C., Dunn A.J., Muglia L.J., et al. Stress-induced behaviors require the corticotropin-releasing hormone (CRH) receptor, but not CRH. Proc Natl Acad Sci U S A 1999, 96:8283-8288.
262. Wetzler S., Asnis G.M., DeLecuona J.M., et al. Serotonin function in panic disorder: intravenous administration of meta-chlorophenylpiperazine. Psychiatry Res 1996, 64:77-82.
263. Wirz-Justice A., Benedetti F., Berger M., et al. Chronotherapeutics (light and wake therapy) in affective disorders. Psychol Med 2005, 35:939-944.
264. Woo T.U., Walsh J.P., Benes F.M. Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Arch Gen Psychiatry 2004, 61:649-657.
265. Wray N.R., James M.R., Gordon S.D., et al. Accurate, large-scale genotyping of 5HTTLPR and flanking single nucleotide polymorphisms in an association study of depression, anxiety, and personality measures. Biol Psychiatry 2009, 66:468-476.
266. Wu Y.H., Fischer D.F., Kalsbeek A., et al. Pineal clock gene oscillation is disturbed in Alzheimer's disease, due to functional disconnection from the " master clock" . FASEB J 2006, 20:1874-1876.
267. Yatham L.N., Liddle P.F., Shiah I.S., et al. Effects of rapid tryptophan depletion on brain 5-HT(2) receptors: a PET study. Br J Psychiatry 2001, 178:448-453.
268. Yirmiya N., Rosenberg C., Levi S., et al. Association between the arginine vasopressin 1a receptor (AVPR1a) gene and autism in a family-based study: mediation by socialization skills. Mol Psychiatry 2006, 11:488-494.
269. Young E.A., Haskett R.F., Murphy-Weinberg V., et al. Loss of glucocorticoid fast feedback in depression. Arch Gen Psychiatry 1991, 48:693-699.
270. Young E.A., Lopez J.F., Murphy-Weinberg V., et al. Mineralocorticoid receptor function in major depression. Arch Gen hear Psychiatry 2003, 60:24-28.
271. Young S.N., Smith S.E., Pihl R.O., et al. Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacology (Berl) 1985, 87:173-177.
272. Zarate C.A., Payne J.L., Quiroz J., et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 2004, 161:171-174.
273. Zarate C.A., Singh J.B., Carlson P.J., et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006, 63:856-864.
274. Zhang Y., Gray T.S., D'Souza D.N., et al. Desensitization of 5-HT1A receptors by 5-HT2A receptors in neuroendocrine neurons in vivo. J Pharmacol Exp Ther 2004, 310:59-66.
275. Zhang Y., Yu C., Zhou Y., et al. Decreased gyrification in major depressive disorder. Neuroreport 2009, 20:378-380.
276. Zhou J.N., Riemersma R.F., Unmehopa U.A., et al. Alterations in arginine vasopressin neurons in the suprachiasmatic nucleus in depression. Arch Gen Psychiatry 2001, 58:655-662.
277. Zhu H., Karolewicz B., Nail E., et al. Normal [3H]flunitrazepam binding to GABAA receptors in the locus coeruleus in major depression and suicide. Brain Res 2006, 1125:138-146.